Skip to main content
. Author manuscript; available in PMC: 2025 Jan 1.
Published in final edited form as: Nucl Med Biol. 2023 Dec 25;128-129:108873. doi: 10.1016/j.nucmedbio.2023.108873

Table 4:

Results from Testing of the Second Production Pathway

Release Criteria Specification Test 1B Test 2B Test 3B
Appearance Clear, Colorless, No Particulates Clear, Colorless, No Particulates Clear, Colorless, No Particulates Clear, Colorless, No Particulates
Filter Integrity > 40 psi 48 psi 47 psi 49 psi
pH 4 – 8 4.5 4.0 4.0
Radiochemical Purity ≥ 90% 99.6 % 99.5 % 98.4 %
Molar Activity ≥ 18.5 GBq/μmol
(≥ 500 Ci/mmol)
1164 GBq/μmol
(31450 Ci/mmol)
747 GBq/μmol
(20181 Ci/mmol)
1166 GBq/μmol
(31510 Ci/mmol)
Residual Solvent ≤ 5000 ppm MEK 16 ppm 16 ppm 16 ppm
Formulation NMT 10% EtOH 6.8 % 6.7 % 6.8 %
Total Chemical Impurities NMT 50 μg/dose 0.264 μg/mL 0.354 μg/mL 0.268 μg/mL
Activity in Final Vial 3.85 GBq
(104 mCi)
3.7 GBq
(100 mCi)
2.68 GBq
(72.5 mCi)
Concentration 294 MBq/mL
(7.94 mCi/mL)
310 MBq/mL
(8.39 mCi/mL)
216 MBq/mL
(5.83 mCi/mL)